Navigation Links
New Study Results Provide Additional Data about Short- and,Long-Term Use of Desvenlafaxine Succinate in the Treatment of,Adults with Major Depressive Disorder

ent in the double-blind study was depression, reported by 4 percent of patients who took desvenlafaxine succinate and 8 percent of placebo patients. The most frequent adverse events with desvenlafaxine succinate in the double-blind phase included headache, nausea, dizziness, asthenia, abnormal dreams and sweating.

The double-blind study population included 375 adults, 18 to 75 years old, with a primary diagnosis of MDD who participated in an initial 12-week, open- label study of desvenlafaxine succinate at doses ranging from 200 to 400 mg/day (desvenlafaxine succinate group, n=190; placebo group, n=185). The primary efficacy endpoint in the double-blind phase of the study was time until relapse, defined by a HAM-D17 score greater than or equal to 16 at any visit; Clinical Global Impressions Scale -- Improvement score greater than or equal to 6 at any visit; or discontinuation due to unsatisfactory response. The study also assessed the response and remission of desvenlafaxine succinate vs. placebo as a secondary objective.

Poster NR344: Ferguson J, et al. A 12-Month, Open-Label Evaluation of Long-Term Safety and Efficacy of Desvenlafaxine Succinate in Outpatients with Major Depressive Disorder

The results are from a Phase 3, multicenter, open-label, flexible-dose study. This study included 104 adults, 18 to 75 years old, with a primary diagnosis of MDD who took doses of desvenlafaxine succinate ranging from 200 to 400 mg/day over a 12-month period. The primary objective was to evaluate the long-term safety of desvenlafaxine succinate as determined by monitoring a variety of indices, including adverse events, patient discontinuation due to adverse events, electrocardiograms, vital signs and the results of laboratory tests. The secondary objective was to evaluate the efficacy of desvenlafaxine succinate by using mean HAM-D17 total scores.

Study findings showed that the most frequent treatment-emergent adverse events were nausea and headache.
'"/>




Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Post Your Comments:
(Date:7/28/2014)... -- Concord Medical Services Holdings Limited ("Concord Medical" or ... specialty hospital management solution provider and operator of the ... China , today announced that on ... special cash dividend of US$0.30 per ordinary share (or ... outstanding ordinary shares. The total expense for the special ...
(Date:7/28/2014)... TOKYO , July 28, 2014  ImaginAb, Inc. ... Roger Crystal , MD as Vice President of Business ... Business Development Product Acquisition & Licensing team at G.E. ... business strategy and partnerships in the precision medicine space ... with biotechnology and pharmaceutical companies across the spectrum to ...
(Date:7/28/2014)... 2014   Cardioxyl Pharmaceuticals, Inc. announced today ... CXL-1427, a novel potential treatment for acute decompensated heart ... company has now initiated dosing of hospitalized patients with ... designed to further evaluate the drug,s safety and tolerability ... Phase I clinical trial evaluated the safety and tolerability ...
Breaking Medicine Technology:Concord Medical Declares Special Dividend 2ImaginAb Appoints Roger Crystal, MD as Vice President of Business Development 2Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427 2
(Date:7/29/2014)... Lean and Lovely, an affordable and short program, claims ... wear a bikini in the near future. This has caught ... , “Our Lean and Lovely review shows that ... levels. Neither your age nor your body shape matters, which ... the beginning, you will achieve the results that you have ...
(Date:7/29/2014)... 29, 2014 Current Back2Basics long-term drug ... medication post foot surgery during his first six months of ... surgery – twice on one foot, once on the other– ... broke my foot a year ago and was prescribed drugs ... Jon by a friend from home who’d recently completed the ...
(Date:7/29/2014)... PeopleKeys today announced that they are launching ... to train and certify others in applied DISC behavioral ... , will be taught by PeopleKeys Master Coach Dan ... as a live Tele-course over the span of 10 ... Consultant Trainer course will use a combination of real-time ...
(Date:7/29/2014)... Maui, HI (PRWEB) July 29, 2014 Couples ... Seasons Resort Maui at Wailea. This September through November, ... of them free-- tailored to couples of all ages and ... and guests can take advantage of the Resort's popular ... $1,000 while the "twice yearly sale" is in full swing ...
(Date:7/29/2014)... 2014 In today’s world, a good night’s ... Snoring and sleep apnea (a medical problem where the airway ... bed partners of the rest they need to face their ... snores and 20 million people in the United States alone ... and treated; and of those treated, many cannot tolerate their ...
Breaking Medicine News(10 mins):Health News:Lean and Lovely: Review Examining Neghar Fonooni’s Program Released 2Health News:Back2Basics Sober Living Resident Overcomes Obstacle in Early Sobriety 2Health News:PeopleKeys Announces New Certified Behavioral Consultant Trainer Course 2Health News:PeopleKeys Announces New Certified Behavioral Consultant Trainer Course 3Health News:Four Seasons Resort Maui at Wailea Goes All Out to Give Couples Memorable Get-Away this Fall at Maui’s Luxury Resort 2Health News:Four Seasons Resort Maui at Wailea Goes All Out to Give Couples Memorable Get-Away this Fall at Maui’s Luxury Resort 3Health News:Snoring: Bad for Relationships, Bad for Health 2Health News:Snoring: Bad for Relationships, Bad for Health 3
... , Anti-Abortion Extremist Ejected After "Murder" ... night in northern Virginia, Representative James Moran and Governor Howard Dean ... by thousands of people. Anti-abortion extremist Randall Terry, the founder of ... be there to disrupt it by accusing President Obama of "killing ...
... reporting development of a new electronic sensor that shows promise ... tests now used to detect DNA. Such tests are ... new lab-on-a-chip test could lead to wider, more convenient use ... for the Sept. 2 issue of the Journal of ...
... Fla., Aug. 26 The only effective solution with proven performance to manage ... The RISS System(TM) removes the inorganic and organic sulfur based contaminants ... it is in Patent Pending status with the U.S. Office of Patents and ... www.RISS s y s tem . com ...
... , , LOS GATOS, Calif., Aug. 26 ... how she survived an airplane crash. Inspiring her audiences with her experience ... Bay area September/early October. , , She says, ... My life was full of stress, illness and failure. After major surgery ...
... , JERICHO, N.Y., Aug. 26 Optimum ... New York metropolitan area businesses, today announced that Medical ... in Long Island, has selected Optimum Lightpath as its ... Optimum Lightpath,s 100% fiber Ethernet connection, Medical Arts Radiology ...
... MORRIS PLAINS, N.J., Aug. 26 New entries in the eye ... eyes. , , "Eye irritation comes in ... including indoor and outdoor irritants and allergens like dust, pollen and ragweed, ... Brisco, O.D. "Since many people experience more than one symptom ...
Cached Medicine News:Health News:Randall Terry Removed By Police From Howard Dean Health Care Town Hall Meeting 2Health News:Proven Solution for Chinese Drywall is Now Available 2Health News:Australia's Contribution to Health and Ultra-longevity 2Health News:Medical Arts Radiology Chooses Optimum Lightpath to Speed Anytime, Anywhere Access to Patient Data and Communications 2Health News:Medical Arts Radiology Chooses Optimum Lightpath to Speed Anytime, Anywhere Access to Patient Data and Communications 3Health News:Breakthroughs in Eye Care Products Offer Fresh Approach for Soothing Eyes 2
... precision, ergonomics, and value!, Comfortable ... soft non-slip, contoured handle , Finer ... plunger spring action , Completely autoclavable ... the need for recalibration , Easy-to-read ...
... 48-capillary 3730 DNA Analyzer, upgradeable to 96 ... DNA analysis. , Higher optical sensitivity ... higher-quality data at a lower cost. , ... , Optimized polymers increase your productivity without ...
The Pipetman Large-Volume Kit includes two large-volume pipettes conveniently packaged with filters and tips at an exceptional price....
... an immunochromatography based one step in vitro ... Opiates and its metabolite in human urine,specimens. ... above a cut-off level of 300 ng/mL,can ... evaluated in the point of care location ...
Medicine Products: